The motion denied Amgen's bid for a temporary injunction that would have prevented the launch of Zarxio, the first FDA-approved biosimilar and a competitor to Amgen's Neupogen.
from Most popular articles from Medical Marketing and Media http://ift.tt/1UtfbuW
No comments:
Post a Comment